{
  "drug_name": "Cefuroxime",
  "tradename": "Ceftin, Zinacef",
  "usage_and_dosing": {
    "general": [
      "Cefuroxime is an intravenous 2nd generation cephalosporin with enhanced activity against H. influenzae (as compared to 1st generation cephalosporins). Retains activity against MSSA, Penicillin-sensitive Strep. pneumoniae, Strep. pyogenes, E. coli, P. mirabilis and Klebsiella sp.",
      "Parenteral use is limited to less severe skin and skin structure infections and surgical prophylaxis (alternative to cefazolin for head and neck, cardiac surgery).",
      "For oral drug, see Cefuroxime axetil.",
      "More stable vs staphylococcal áºž-lactamase than Cefazolin.",
      "For cross-allergenicity and other class-wide adverse effects, see Cephalosporins, Overview. See also Penicillin (Beta Lactam) Allergy Overview."
    ],
    "adult_dose": {
      "usual_dose": "750 mg IV/IM q8h",
      "more_serious_infections": "Can increase to 1.5 gm IV q6h",
      "surgical_prophylaxis": "1.5 gm within 60 mins of surgical incision"
    },
    "pediatric_dose": {
      "standard": "150 mg/kg/day (divided q8h)",
      "meningitis": "240 mg/kg/day (divided q8h)"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "1.5",
    "half_life_esrd": "17",
    "dose_renal_function_normal": "0.75-1.5 gm IV q8h",
    "crcl_or_egfr": "CrCl >50: No dosage adjustment. CrCl 10-50: 0.75-1.5 gm q8-12h. CrCl <10: 0.75-1.5 gm q24h",
    "hemodialysis": "0.75-1.5 gm q24h (AD on dialysis days)",
    "capd": "0.75-1.5 gm q24h",
    "crrt": "0.75-1.5 gm q8-12h",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "adverse_effects": [
    "Local phlebitis (2%), rash (rare), positive Coombs (rare), neutropenia (rare), eosinophilia (7%), nausea/vomiting (rare), diarrhea (4-11%), C. difficile colitis, increased LFTs (4%).",
    "For cross-allergenicity and other class-wide adverse effects, see Cephalosporins, Overview."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "lactation": "Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "100 (1.5 gm IV, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "33-50",
    "volume_of_distribution_vd_l_kg_vss": "0.19 L/kg (Vss)",
    "avg_serum_half_life_hr": "1.5",
    "elimination": "Renal",
    "bile_penetration_percent": "35-80",
    "csf_blood_percent": "17-88",
    "therapeutic_levels_in_csf": "Marginal",
    "auc_ug_hr_ml": "150 (1.5 gm IV, 0-inf)"
  },
  "enzyme_transporter_mediated_interactions": {
      "cyp450s_substrate": [],
      "transporters_substrate": ["OAT1", "OAT3"],
      "ugts_substrate": [],
      "cyp450s_inhibited": [],
      "transporters_inhibited": [],
      "ugts_inhibited": [],
      "cyp450s_induced": [],
      "transporters_induced": [],
      "ugts_induced": [],
      "impact_on_serum_drug_concentrations": "None expected"
  },
  "major_drug_interactions": [
    "No significant interactions"
  ],
  "comments": []
}
